A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia

Trial Profile

A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2017

At a glance

  • Drugs Vincristine (Primary) ; Asparaginase; Dexamethasone; Mitoxantrone
  • Indications Lymphoid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 May 2017 Planned End Date changed from 1 Mar 2019 to 1 May 2021.
    • 11 May 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Aug 2020.
    • 13 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top